Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Runimotamab dose-escalation study in advanced HER2-expressing cancers
NL-OMON54065Phase 1Recruiting
- Sponsor
- Genentech
- Start
- Apr 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of runimotamab in breast cancer, gastric cancer (GC), gastroesophageal junction adenocarcinoma and 1 more (2 arms), sponsored by Genentech. Primary endpoints: Adverse events, Left ventricular ejection fraction change and 4 more. Started Apr 2022; status: recruiting.
02
Drugs
runimotamab
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction adenocarcinomaHER2-positive cancer (HER2+)
Beyond the preview
Go deeper on NL-OMON54065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54065.